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Summary
Background Concomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care 
systems. We aimed to assess the safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-
appropriate influenza vaccine.
Methods In this multicentre, randomised, controlled, phase 4 trial, adults in receipt of a single dose of ChAdOx1 or 
BNT162b2 were enrolled at 12 UK sites and randomly assigned (1:1) to receive concomitant administration of either 
an age-appropriate influenza vaccine or placebo alongside their second dose of COVID-19 vaccine. 3 weeks later the 
group who received placebo received the influenza vaccine, and vice versa. Participants were followed up for 6 weeks. 
The influenza vaccines were three seasonal, inactivated vaccines (trivalent, MF59C adjuvanted or a cellular or 
recombinant quadrivalent vaccine). Participants and investigators were masked to the allocation. The primary 
endpoint was one or more participant-reported solicited systemic reactions in the 7 days after first trial vaccination(s), 
with a difference of less than 25% considered non-inferior. Analyses were done on an intention-to-treat basis. Local 
and unsolicited systemic reactions and humoral responses were also assessed. The trial is registered with ISRCTN, 
ISRCTN14391248.
Findings Between April 1 and June 26, 2021, 679 participants were recruited to one of six cohorts, as follows: 
129 ChAdOx1 plus cellular quadrivalent influenza vaccine, 139 BNT162b2 plus cellular quadrivalent influenza vaccine, 
146 ChAdOx1 plus MF59C adjuvanted, trivalent influenza vaccine, 79 BNT162b2 plus MF59C adjuvanted, trivalent 
influenza vaccine, 128 ChAdOx1 plus recombinant quadrivalent influenza vaccine, and 58 BNT162b2 plus recombinant 
quadrivalent influenza vaccine. 340 participants were assigned to concomitant administration of influenza and a 
second dose of COVID-19 vaccine at day 0 followed by placebo at day 21, and 339 participants were randomly assigned 
to concomitant administration of placebo and a second dose of COVID-19 vaccine at day 0 followed by influenza 
vaccine at day 21. Non-inferiority was indicated in four cohorts, as follows: ChAdOx1 plus cellular quadrivalent 
influenza vaccine (risk difference for influenza vaccine minus placebo –1·29%, 95% CI –14·7 to 12·1), BNT162b2 
plus cellular quadrivalent influenza vaccine (6·17%, –6·27 to 18·6), BNT162b2 plus MF59C adjuvanted, trivalent 
influenza vaccine (–12·9%, –34·2 to 8·37), and ChAdOx1 plus recombinant quadrivalent influenza vaccine (2·53%, 
–13·3 to 18·3). In the other two cohorts, the upper limit of the 95% CI exceeded the 0·25 non-inferiority margin 
(ChAdOx1 plus MF59C adjuvanted, trivalent influenza vaccine 10·3%, –5·44 to 26·0; BNT162b2 plus recombinant 
quadrivalent influenza vaccine 6·75%, –11·8 to 25·3). Most systemic reactions to vaccination were mild or moderate. 
Rates of local and unsolicited systemic reactions were similar between the randomly assigned groups. One serious 
adverse event, hospitalisation with severe headache, was considered related to the trial intervention. Immune 
responses were not adversely affected.
Interpretation Concomitant vaccination with ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine raises 
no safety concerns and preserves antibody responses to both vaccines. Concomitant vaccination with both COVID-19 
and influenza vaccines over the next immunisation season should reduce the burden on health-care services for vaccine 
delivery, allowing for timely vaccine administration and protection from COVID-19 and influenza for those in need.
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Introduction 
COVID-19 vaccination programmes have prevented 
millions of cases of SARS-CoV-2 infection and many 
deaths around the world.1 However, mass vaccination 
efforts have added to the burden placed by the COVID-19 
pandemic on health-care systems. In some parts of the 
world, COVID-19 and seasonal influenza vaccination 
programmes will overlap, and so administration of both 
vaccines at the same appointment, concomitantly, could 
lessen the burden on health-care systems, support 
vaccine uptake, and afford timely protection against both 
infections. High rates of influenza, alongside further 
waves of COVID-19, are predicted for the coming 
northern hemisphere winter, as there was little 
circulating influenza virus detected during the first wave 
of the COVID-19 pandemic.2 Therefore, it is important 
that further doses of COVID-19 and influenza vaccines 
are delivered in a timely, efficient, and safe manner.
International recommendations in the 2020–21 
influenza season were to separate influenza and 
COVID-19 vaccines by 14 days.3,4 The main reasons for 
this were to avoid inaccurate attribution of side-effects to 
the newly approved COVID-19 vaccines and insufficient 
data to inform concomitant vaccination. It is necessary to 
establish whether concomitant vaccination is safe and 
whether this would increase reactogenicity rates, as 
increased rates might negatively influence vaccine 
uptake—this is particularly important as the most widely 
used COVID-19 vaccines produce relatively high rates of 
expected systemic adverse reactions, such as fever, 
compared with other vaccines.5,6 Additionally, in some 
cases concomitant vaccination alters the immunogenicity 
of administered vaccines.7
In this study, we investigated the safety and 
immunogenicity of concomitant administration of a 
COVID-19 vaccine (either an adenovirus viral vector 
COVID-19 vaccine, ChAdOx1, or an RNA COVID-19 
vaccine, BNT162b2) with an inactivated influenza vaccine 
(either an MF59C adjuvanted, trivalent vaccine or a 
cellular or recombinant quadrivalent vaccine). 
Methods 
Study design and participants 
ComFluCOV was a multicentre, randomised, controlled, 
phase 4 trial with masking, across 12 UK National Health 
Service (NHS) sites (appendix p 35) across the UK. 
The trial was designed to investigate concomitant 
administration of second doses of two COVID-19 
vaccines (ChAdOx1; Oxford–AstraZeneca and BNT162b2; 
Pfizer–BioNTech) with three influenza vaccines (MF59C 
adjuvanted, trivalent vaccine, cellular quadrivalent 
vaccine, and recombinant quadrivalent vaccine). Partici-
pants were recruited into one of six cohorts defined by 
the six COVID-19 and influenza vaccine combinations.
The trial was done in accordance with the principles of 
the Declaration of Helsinki and Good Clinical Practice. 
Approvals were received from the Medicines and 
Healthcare products Regulatory Agency (MHRA; 
EudraCT number 2021-001124-18) and the South-Central 
Berkshire Research Ethics Committee (21/SC/0100). The 
trial was sponsored by University Hospitals Bristol and 
Weston NHS Foundation Trust and coordinated by the 
Bristol Trials Centre, University of Bristol (Bristol, UK). 
The protocol is included in the appendix (pp 3–33).
Two substantial amendments were made to the study 
protocol. An influenza vaccine (recombinant quadrivalent 
vaccine) was added after the start of recruitment at the 
request of the UK Department of Health and Social Care 
(DHSC). The sample size was increased from 504 to 
756 and the number of cohorts increased from four 
to six. In response to the Urgent Safety Measure initiated 
by the MHRA on April 8, 2021, in relation to incidents of 
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Research in context
Evidence before this study
We did a search of PubMed from inception to Sept 10, 2021, 
restricted to papers published in English. Search terms included 
“influenza vaccine”, “COVID-19 vaccine”, “concomitant”, and 
“co-administration”. No published studies relating to influenza 
and COVID-19 vaccine co-administration were found. We were 
aware of one study published as a preprint. In this preprint, 
concomitant administration of an age-appropriate influenza 
vaccine and the first dose of a novel subunit COVID-19 vaccine 
was shown to have similar reactogenicity profiles to 
administration of the COVID-19 vaccine alone. However, 
concomitant administration resulted in a reduction in the 
anti-spike IgG concentration response to COVID-19 vaccine 
compared with COVID-19 vaccination alone, but with no effect 
on efficacy. Data on concomitant administration of other types 
of COVID-19 vaccine and influenza vaccine are needed to 
inform public health policy in the UK. 
Added value of this study
This trial presents data to support the concomitant 
administration of second doses of the ChAdOx1 and 
BNT162b2 COVID-19 vaccines with age-appropriate 
inactivated influenza vaccines. We show that concomitant 
vaccination is possible as it raises no safety concerns, most 
systemic reactions are mild or moderate, and the immune 
response is not adversely affected.
Implications of all the available evidence
These data will inform public health policy in the UK relating 
to seasonal influenza vaccine delivery, alongside second and 
potentially later doses of both ChAdOx1 and BNT162b2 
COVID-19 vaccines in adults. Concomitant vaccination might 
reduce the burden on health-care services and could support 
public vaccine uptake.
See Online for appendix
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thromboembolic events after vaccination with ChAdOx1, 
recruitment of those aged under 30 years in receipt of 
ChAdOx1 was temporarily suspended on April 9, 2021, 
and then resumed on April 14, 2021. Exclusion criteria 
were updated to exclude participants at risk of thrombotic 
events.
We used social media and local advertising to raise 
awareness of the trial. Volunteers registered their interest 
by completing an online questionnaire. Volunteers were 
eligible if they were aged 18 years and older and had 
received a single dose of either ChAdOx1 in the preceding 
56–90 days or BNT162b2 in the preceding 28–90 days, in 
line with UK recommendations. Volunteers had to agree 
to their general practitioner being contacted and to 
refrain from blood donation in the 7 days after vac-
cination, and needed access to an electronic device. 
Volunteers were ineligible if they had received any other 
vaccine in the 30 days before recruitment or had received 
immunoglobulins or blood products in the previous 
3 months, had a history of allergy or reactions to any 
component of the trial vaccines, had a bleeding disorder 
or continuous use of anticoagulants, suspected or known 
drug or alcohol dependence, or a progressive neurological 
disorder. Partway through the trial, the exclusion criteria 
were updated to exclude volunteers at risk of thrombotic 
events, in line with UK recommendations. Participants 
with other comorbidities that made them eligible for 
routine influenza vaccine were included (appendix p 38). 
Full inclusion and exclusion criteria are provided in the 
appendix (pp 10–11). Written informed consent was 
received from all participants at the first trial visit (day 0).
Randomisation and masking 
At day 0, participants were randomly assigned (1:1) to 
receive either an age-appropriate influenza vaccine or a 
placebo injection, alongside their second dose of a 
COVID-19 vaccine homologous to their first dose, using 
a secure internet-based system to ensure allocation 
concealment. The randomisation schedule was stratified 
by cohort, with blocks of varying size. The sequence was 
generated by a statistician who was not otherwise 
involved in the trial.
Participants, clinicians assessing causality of adverse 
events, and laboratory staff were masked to the treatment 
allocation. Vaccines were prepared out of sight of the 
participant, and masking was maintained by asking 
participants to look away during the injection and 
applying a masking label over the vaccine syringe. Trial 
staff who administered the vaccines and entered these 
data were not masked.
Procedures 
At day 0, eligible volunteers who consented to take part 
were randomly assigned and received the trial 
vaccinations (ie, either an age-appropriate influenza 
vaccine or a placebo injection in addition to their second 
dose of a COVID-19 vaccine). At the second visit between 
21 days and 28 days later (day 21), those who received an 
influenza vaccine at day 0 received a placebo injection 
and vice versa. Participants attended a final trial visit at 
between 42 days and 56 days (day 42) for safety 
assessments. Participants provided up to 10 mL of sera 
and up to 2 mL of saliva at all three trial visits.
ChAdOx1 (0·5 mL dose) is a recombinant, replication-
deficient chimpanzee adenovirus vectored vaccine, 
expressing the SARS-CoV-2 spike surface glycoprotein 
with a leading tissue plasminogen activator signal 
sequence. BNT162b2 (0·3 mL dose) is a lipid nanoparticle-
formulated, nucleoside-modified mRNA vaccine encoding 
trimeric SARS-CoV-2 spike glycoprotein.
The influenza vaccines used were in keeping with 
age-based influenza vaccine recommendations in the 
UK. Adults aged 65 years and older received FluAd 
(Seqirus UK; Maidenhead, UK) a trivalent, surface 
antigen inactivated influenza vaccine adjuvanted with 
MF59C. Adults younger than 65 years received one of 
two quadrivalent influenza vaccines: Flucelvax (Seqirus 
UK), a surface antigen, inactivated vaccine prepared in 
cell culture, or Flublok (Sanofi; Paris, France) a 
recombinant influenza vaccine. The influenza vaccines 
were from the 2020–21 season and contained A strains 
(H1N1 and H3N2) and B strains (Yamagata and Victoria) 
that complied with WHO recommendations for the 
northern hemisphere. The influenza vaccines were 
provided in commercially available pre-filled syringes as 
a 0·5 mL dose. Commercially available 0·5 mL of sodium 
chloride injection BP 0·9% was used as a saline placebo. 
Influenza vaccine(s) available at each participating site 
are shown in the appendix (p 35). Study sites only had 
one quadrivalent vaccine available; therefore the 
allocation was dependent on enrolment site.
All vaccines were administered intramuscularly in the 
upper arm by appropriately trained staff at trial sites. 
The COVID-19 vaccine was given in one arm and the 
influenza vaccine or placebo was given in the other arm. 
The upper thigh was used if the arm could not be used. 
Participants were observed for at least 15 min after 
vaccination.
Outcomes 
The primary outcome was one or more solicited systemic 
reactions in the 7 days after vaccination at day 0. The 
solicited systemic reactions were fever (body temperature 
>38°C, with or without symptoms), feverishness (feeling 
hot, sweating, and shivery, with or without an elevated 
body temperature), chills, joint pains, muscle pains, 
fatigue, headache, malaise, nausea, vomiting, and 
diarrhoea. Reactions were collected daily via a purpose-
designed participant-completed electronic diary. Partici-
pants were asked to record their temperature each day, 
which was used to assess fever, and were provided with 
an oral thermometer for this purpose.
Secondary outcomes included safety and reactogenicity 
as measured by solicited local reactions (namely pain, 
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tenderness, redness, warmth, itch, swelling, and 
induration in the 7 days after vaccination at day 0 and 
day 21; tenderness was not captured explicitly but was 
covered under pain), solicited systemic reactions (as 
listed for the primary outcome) in the 7 days after 
vaccination at day 21, and unsolicited adverse events for 
the whole trial period. Adverse events included serious 
adverse events, medically attended adverse events, and 
adverse events of special interest. The local research 
team reviewed diary entries daily to assess adverse events 
for severity, determined in accordance with US Food and 
Drug Administration toxicity grading criteria.8 Diaries 
were also reviewed at trial visits, when any adverse events 
not captured in the diary were collected.
Secondary immunological outcomes included 
SARS-CoV-2 spike-protein immunoglobulin concen-
tration in serum samples collected at day 0 and day 21 
analysed using the Elecsys anti-SARS-CoV-2 S elec-
trochemiluminescence immunoassay (Roche; Basel, 
Switzerland)9 and haemagglutinin antibody inhibition in 
sera collected at day 0, day 21, and day 42 against the four 
strains of influenza vaccine virus (H1N1, H3N2, 
Yamagata, and Victoria) contained in the 2020–21 season 
vaccines using a validated assay.10 To maintain masking, 
all serum samples, including from those who received 
the trivalent vaccine, were tested for all four influenza 
strains. All assays were done at Porton Down, UK by 
Public Health England (PHE).
Other immunological outcomes, which will be reported 
in a subsequent publication, included measurement of 
neutralising antibodies against SARS-CoV-2 from serum 
samples at day 0 and day 21 to assess the response to a 
second dose of COVID-19 vaccine and mucosal immune 
responses to COVID-19 vaccines in saliva. These data 
were not available at the time of writing.
Qualitative outcomes included days of work lost (if 
employed), acceptability to participants of future 
concomitant vaccine administration, and an assessment 
of the success of participant masking using the Bang 
Blinding Index11 completed at day 42. Participants were 
asked to indicate which group they thought they were 
allocated to (influenza first, placebo first, or did not 
know). The index ranges from –1 to 1, with 0 indicating 
successful blinding. A positive value indicates more 
correct guesses than expected by chance and gives an 
indication of the proportion of participants unblinded.
Statistical analysis 
The sample size was set at 126 participants per cohort 
(756 in total), which provided 80% power to assess the non-
inferiority of concomitant administration of COVID-19 
and influenza vaccine compared with COVID-19 vaccine 
alone, assuming a primary outcome frequency of 50% and 
a non-inferiority margin of 25%. The non-inferiority 
margin was agreed by the clinical members of the study 
team, and was both acceptable and requiring a sample size 
that was achievable in the timescale for the study.
Analyses were done on an intention-to-treat basis. A per-
protocol analysis, and sensitivity analyses imputing 
missing outcome data were also done for the primary 
outcome (appendix p 26). Binary outcomes were compared 
using a generalised linear model, and risk differences and 
risk ratios are reported. Count variables were analysed 
using Poisson regression and continuous variables were 
analysed using a mixed regression model. Models included 
cohort by treatment by time interactions to allow changes 
in treatment effect with time within each cohort to be 
described. Analyses were adjusted for baseline measures 
(where recorded) and for participant and trial site fitted as 
random effects (where estimable; see appendix p 26). 
Immunogenicity outcomes were transformed to the 
logarithmic scale (base 10) for analysis and results are 
presented as geometric mean ratios. Placebo injection at 
day 0 was used as the reference group.
Unsolicited adverse events were coded using 
version 23.1 of the Medical Dictionary for Regulatory 
Activities and summarised by severity and relationship to 
the trial vaccine. Seroconversion for anti-spike protein 
immunoglobulin concentration was defined as a 4-times 
increase in the Elecsys anti-SARS-CoV-2 S electro-
chemiluminescence immunoassay units from day 0 to 
day 21 and for haemagglutinin antibody inhibition titres 
seroconversion was defined as a post-vaccination titre of 
at least 32 if the baseline titre was less than eight and a 
4-times increase if the baseline titre was eight or more.
Concomitant administration of the two vaccines was 
considered non-inferior to the COVID-19 vaccine alone if 
the upper limit of the 95% CI for the risk difference for 
the primary outcome of any solicited systemic reaction in 
the 7 days after concomitant vaccination at day 0 was less 
than 0·25 in both the intention-to-treat and per-protocol 
analyses.
Statistical analysis was done using STATA release 17. 
An independent data monitoring and safety committee 
reviewed trial safety data. The trial is registered with 
ISRCTN, ISRCTN14391248.
Role of the funding source 
The funders determined which vaccines were used in the 
trial, but had no role in data collection, data analysis, data 
interpretation, or writing of the report. COVID-19 
vaccines were supplied by PHE and influenza vaccines 
were supplied by the DHSC.
Results 
Between April 1 and June 26, 2021, 679 participants were 
enrolled and randomly assigned—340 participants were 
assigned to concomitant administration of influenza and 
a second dose of COVID-19 vaccine at day 0 followed by 
placebo at day 21, and 339 participants were randomly 
assigned to concomitant administration of placebo and a 
second dose of COVID-19 vaccine at day 0 followed by 
influenza vaccine at day 21 (figure 1). For two of the 
cohorts—BNT162b2 plus MF59C adjuvanted, trivalent 
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vaccine and BNT162b2 plus recombinant quadrivalent 
vaccine—fewer participants than planned were enrolled 
(79 [63%] of 126 and 58 [46%] of 126, respectively).
One participant was considered ineligible after ran-
domisation because of raised blood pressure so did not 
receive any trial vaccinations. For four participants, the 
incorrect cohort randomisation scheme was selected, but 
the correct vaccines were administered (appendix p 36). 
These participants were analysed according to the 
COVID-19 and influenza vaccines received. A further two 
Figure 1: Trial profile
Placebo first indicates that COVID-19 vaccine alone was received at day 0. Influenza first indicates that concomitant COVID-19 and influenza vaccines were received at day 0. *Pre-screening 







































































































































































































































































































































































































129 assigned to ChAdOx1 plus
cellular quadrivalent vaccine
139 assigned to BNT162b2 plus 
cellular quadrivalent vaccine
146 assigned to ChAdOx1 plus 
MF59C adjuvanted, trivalent 
vaccine
79 assigned to BNT162b2 plus 
MF59C adjuvanted, trivalent 
vaccine
128 assigned to ChAdOx1 plus 
recombinant quadrivalent 
vaccine
58 assigned to BNT162b2 plus 
recombinant quadrivalent 
vaccine
767 potentially eligible, added to 
study database, and completed 
initial screening telephone call 
3535 participants completed online 
pre-screening questionnaire* 
679 randomly assigned  
88 excluded
 34 ineligible at initial screening
 25 cancelled booked clinic visit 
 21 booked for clinic and did not attend
 5 ineligible at clinic visit




6 www.thelancet.com   Published online November 11, 2021   https://doi.org/10.1016/S0140-6736(21)02329-1
participants were randomly assigned using the correct 
cohort assignment, but received the wrong influenza 
vaccine at day 21; these participants were analysed 
according to the cohort they were randomly assigned to. 
The median time between the two vaccinations at day 0 
was 0 min (IQR 0–1; range 0–176; appendix p 37). Ten (1%) 
participants did not receive a second trial injection at 
day 21 and nine (1%) did not attend at the day 42 visit.
Baseline characteristics were similar across the 
two randomly assigned groups in each cohort (table). 
The median age of participants by influenza vaccine type 
was 51 years (IQR 37–60) for those receiving the cellular 
quadrivalent vaccine, 52 years (41–59) for those receiving 
the recombinant quadrivalent vaccine, and 69 years 
(67–72) for those receiving the MF59C adjuvanted, 
trivalent vaccine. 397 (58%) of 679 participants were 
female and 627 (92%) were White British. No participants 
were known to be pregnant at the time of enrolment, but 
one participant reported that they were pregnant at the 
day 21 visit. In total, 548 (81%) of 679 participants had 
received an influenza vaccine in the 2020–21 season, 
with a higher percentage vaccinated in MF59C 
adjuvanted, trivalent vaccine cohorts (217 [96%] of 
225 participants). Of those younger than 65 years, 
85 (19%) of 454 participants were health-care workers. 
276 (41%) of 679 participants were retired. A range of 
comorbidities associated with an indication for influenza 
vaccine were represented (appendix p 38).
Electronic participant diaries were well completed 
(appendix pp 39–40) and the primary outcome could be 
determined for 651 (96%) of 679 participants. 254 (77%) of 
330 participants in the group that was randomly assigned 
ChAdOx1 plus cellular 
quadrivalent vaccine
BNT162b2 plus cellular 
quadrivalent vaccine
ChAdOx1 plus MF59C 
adjuvanted, trivalent 
vaccine

































Age at screening, years 54 (43–61) 52 (40–57) 47 (34–58) 48 (35–60) 71 (69–72) 69 (67–72) 68 (67–70) 68 (67–70) 52 (44–60) 56 (51–60) 39 (33–47) 42 (31–53)
Sex
Female 38 (59%) 43 (66%) 48 (68%) 51 (75%) 31 (42%) 44 (60%) 14 (37%) 24 (59%) 37 (58%) 34 (53%) 15 (52%) 18 (62%)
Male 26 (41%) 22 (34%) 23 (32%) 17 (25%) 42 (58%) 29 (40%) 24 (63%) 17 (41%) 27 (42%) 30 (47%) 14 (48%) 11 (38%)





57 (89%) 54 (83%) 65 (92%) 60 (88%) 70 (96%) 71 (97%) 38 (100%) 39 (95%) 59 (92%) 64 (100%) 25 (86%) 25 (86%)
White Irish 2 (3%) 2 (3%) 2 (3%) 0 1 (1%) 0 0 0 0 0 0 0
Any other White 
background
3 (5%) 2 (3%) 2 (3%) 3 (4%) 1 (1%) 1 (1%) 0 2 (5%) 1 (2%) 0 2 (7%) 3 (10%)
White and Asian 0 1 (2%) 0 0 0 0 0 0 1 (2%) 0 0 0
Any other mixed or 
multiple ethnic 
background
0 3 (5%) 1 (1%) 2 (3%) 1 (1%) 1 (1%) 0 0 0 0 0 0
Indian 1 (2%) 3 (5%) 0 2 (3%) 0 0 0 0 0 0 1 (3%) 1 (3%)
Pakistani 1 (2%) 0 0 0 0 0 0 0 1 (2%) 0 0 0
Chinese 0 0 0 0 0 0 0 0 1 (2%) 0 0 0
Any other ethnic 
group
0 0 0 1 (1%) 0 0 0 0 1 (2%) 0 1 (3%) 0




15 (23%) 18 (28%) 19 (27%) 21 (31%) 0 0 1 (3%) 0 3 (5%) 3 (5%) 5 (17%) 1 (3%)
Employed— other 30 (47%) 34 (52%) 35 (49%) 33 (49%) 4 (5%) 6 (8%) 7 (18%) 4 (10%) 39 (61%) 43 (67%) 18 (62%) 22 (76%)
Unemployed 4 (6%) 3 (5%) 3 (4%) 2 (3%) 0 0 1 (3%) 0 3 (5%) 3 (5%) 3 (10%) 2 (7%)
Student 2 (3%) 0 4 (6%) 3 (4%) 0 0 0 0 5 (8%) 0 2 (7%) 2 (7%)
Retired 13 (20%) 10 (15%) 10 (14%) 9 (13%) 69 (95%) 67 (92%) 29 (76%) 37 (90%) 14 (22%) 15 (23%) 1 (3%) 2 (7%)
Participant received 
influenza vaccination in 
winter 2020–21 
programme
48 (75%) 48 (74%) 52 (73%) 55 (81%) 72 (99%) 70 (96%) 35 (92%) 40 (98%) 41 (64%) 52 (81%) 22 (76%) 13 (45%)
Data are median (IQR) or n (%). Placebo first indicates that COVID-19 vaccine alone was received at day 0. Flu first indicates that concomitant COVID-19 and influenza vaccines were received at day 0. 
Table: Participant demographics
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to concomitant COVID-19 and influenza vaccines at day 0 
had one or more systemic solicited reactions over 7 days 
after vaccination compared with 239 (75%) of 
321 participants in the group that was randomly assigned 
to COVID-19 vaccine alone at day 0, with fatigue the most 
commonly reported systemic reaction (appendix p 41). 
Concomitant administration of the two vaccines was 
found to be non-inferior to administration of the 
COVID-19 vaccine alone with respect to the primary 
outcome of any systemic adverse reaction in the 7 days 
after day 0 in four cohorts: ChAdOx1 plus cellular 
quadrivalent influenza vaccine (risk difference for 
influenza vaccine minus placebo –1·29%, 95% CI 
–14·7 to 12·1), BNT162b2 plus cellular quadrivalent 
influenza vaccine (6·17%, –6·27 to 18·6), BNT162b2 plus 
MF59C adjuvanted, trivalent influenza vaccine (–12·9%, 
–34·2 to 8·37), and ChAdOx1 plus recombinant 
quadrivalent influenza vaccine (2·53%, –13·3 to 18·3). In 
the other two cohorts, the upper limit of the 95% CI 
exceeded the 0·25 non-inferiority margin (ChAdOx1 plus 
MF59C adjuvanted, trivalent influenza vaccine 10·3%, 
–5·44 to 26·0; BNT162b2 plus recombinant quadrivalent 
influenza vaccine 6·75%, –11·8 to 25·3; figure 2; appendix 
p 42). The only major protocol deviation recorded was an 
ineligible participant who was randomly assigned in error 
with high blood pressure. This patient did not complete 
any diary entries. The per-protocol analyses are therefore 
identical to the intention-to-treat analyses. Risk ratios and 
results of the sensitivity analyses are shown in the 
appendix (pp 43–44). In all cohorts most systemic reactions 
were mild or moderate. 14 (5%) of 254 participants who 
reported one or more systemic reactions in the 
concomitant COVID-19 and influenza vaccine group 
reported at least one severe adverse reaction compared 
with six (3%) of 239 participants in the COVID-19 vaccine 
alone group. There were four severe systemic reactions 
(feverishness, chills, headache, and malaise) in the 
ChAdOx1 plus MF59C adjuvanted, trivalent influenza 
vaccine cohort, reported by two participant(s), both of 
whom received the MF59C adjuvanted, trivalent influenza 
vaccine at day 0, and three severe systemic reactions in the 
BNT162b2 plus recombinant quadrivalent vaccine cohort 
(two participants with fatigue and malaise in the group 
that received the placebo, and one participant with malaise 
in the group that received the recombinant quadrivalent 
vaccine at day 0; appendix pp 45–46). The proportion of 
participants who reported one or more systemic events 
after receiving either influenza vaccine or saline injection 
at day 21 was similar (appendix pp 47–53). The number of 
different systemic solicited reactions reported by each 
participant was similar in the two randomly assigned 
groups at both timepoints (appendix pp 47–48, 54).
555 (83%) of 665 participants reported at least 
one solicited local adverse reaction after vaccination at 
day 0 (282 [85%] of 331 participants in the concomitant 
COVID-19 and influenza vaccine group and 273 [82%] of 
334 participants in the COVID-19 vaccine alone group), 
with injection site pain the most commonly reported 
reaction in all cohorts (appendix pp 55–56). The number 
of participants reporting one or more local reactions over 
the 7 days after day 0 was similar in the two groups for all 
cohorts (appendix pp 47–48, 57). Most reactions were mild 
or moderate, with eight reports of severe reactions in the 
limb receiving the COVID-19 vaccine—seven reports of 
pain and one report of warmth. There was a significantly 
higher proportion of individuals who reported local 
adverse reactions when receiving the influenza vaccine at 
day 21 compared with those who received placebo 
(appendix pp 57–58), but no severe local reactions were 
reported (appendix pp 52–53). The number of different 
local solicited reactions reported by each participant was 
similar in the two randomly assigned groups after day 0 
Figure 2: Participants reporting one or more solicited systemic adverse reactions in the 7 days after second COVID vaccination plus influenza vaccination or 
placebo—complete case analysis
Placebo first indicates that COVID-19 vaccine alone was received at day 0. Influenza first indicates that concomitant COVID-19 and influenza vaccines were received at 
day 0. QIVc=cellular quadrivalent vaccine. ITT=intention to treat. aTIV=MF59C adjuvanted, trivalent vaccine. QIVr=recombinant quadrivalent vaccine.
 
 
Risk difference (95% CI)Number of participants experiencing one 
or more solicited systemic events in the 
7 days after second COVID-19 vaccination/
number of participants with the primary 
outcome in each group for each cohort
24/2723/28BNT162b2 + QIVr ITT 6·75 (–11·75 to 25·25)
46/6243/60ChAdOx1 + QIVr ITT 2·53 (–13·25 to 18·31)
24/4125/35BNT162b2 + aTIV ITT –12·89 (–34·15 to 8·37)
49/6842/68ChAdOx1 + aTIV ITT 10·29 (–5·44 to 26·03)
59/6854/67BNT162b2 + QIVc ITT 6·17 (–6·27 to 18·61)
–1·29 (–14·69 to 12·11)52/6452/63ChAdOx1 + QIVc ITT
Risk difference (95% CI)
–50 –25 0 25 50
Favours influenza first Favours placebo first
Placebo first Influenza first
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but was significantly higher after day 21 in the 
COVID-19 vaccine alone group who received the influenza 
vaccine at day 21 (appendix pp 47–48, 58).
There were 173 unsolicited adverse events after vacci-
nation reported by 112 participants in the concomitant 
COVID-19 and influenza vaccine group after day 0 and 
155 unsolicited adverse events reported by 99 participants 
in the COVID-19 vaccine alone group. After day 21, 
66 unsolicited adverse events were reported by 
49 participants in the concomitant COVID-19 and 
influenza vaccine group compared with 84 unsolicited 
adverse events reported by 57 participants in the 
COVID-19 alone group (appendix pp 47–48, 59–66). Rates 
of medically attended adverse events were similar 
between groups after day 0 (25 medically attended adverse 
events reported by 22 participants in the concomitant 
COVID-19 and influenza vaccine group and 27 medically 
attended adverse events reported by 20 participants in the 
COVID-19 alone group) and after day 21 (18 medically 
attended adverse events reported by 15 participants in the 
concomitant COVID-19 and influenza vaccine group who 
received placebo at day 21 compared with 15 medically 
attended adverse events reported by 14 participants in the 
COVID-19 alone group who received the influenza 
vaccine at day 21; appendix pp 47–48, 67–71).
Seven serious adverse events were reported by seven 
participants, including one considered related to 
vaccination. A participant was admitted to hospital with 
severe headache and visual disturbance 48 h after 
vaccination with ChAdOx1 and influenza and given a 
diagnosis of migraine (appendix pp 47–48, 71). One adverse 
event of special interest—mild chilblain-like lesions—was 
reported as starting 4 days after vaccination with ChAdOx1 
and saline placebo. The lesions resolved within 7 days 
with no ongoing sequelae and were reported as having a 
possible association with vaccination (appendix p 72).
Anti-spike immunoglobulin geometric mean units, 
measured 21 days after receiving either ChAdOx1 or 
BNT162b2, were similar between those who received 
concomitant vaccination or COVID-19 alone in all cohorts 
(figure 3). Seroconversion rates ranged from 89% to 100% 
and 79% to 93% 21 days after either BNT162b2 or ChAdOx1, 
respectively, when given concomitantly with the influenza 
vaccine or COVID-19 vaccine alone (appendix pp 73–75).
No significant differences were seen in the haem-
agglutinin antibody inhibition geometric mean ratio for 
any influenza strain 21 days after receiving influenza 
vaccine with a COVID-19 vaccine compared with receiving 
the influenza vaccine alone in the cellular quadrivalent 
vaccine and MF59C adjuvanted, trivalent vaccine cohorts 
or in the cohort that received ChAdOx1 plus recombinant 
quadrivalent influenza vaccine (figure 4). In the BNT162b2 
plus recombinant quadrivalent influenza vaccine cohort, 
the geometric mean titres of A/H1N1 and both B strains 
were higher when given with BNT162b2 compared with 
when recombinant quadrivalent influenza vaccine was 
given alone but were similar for A/H3N2 (figure 4; 
appendix p 76). Seroconversion rates ranged from 
1% to 72%, tending to be lower in the MF59C adjuvanted, 
trivalent influenza vaccine cohorts than in either of the 
quadrivalent influenza vaccine cohorts, and lower for B 
strains compared with A strains (appendix p 59).
Nine (1%) of 670 participants reported that they would 
not be willing to receive concomitant vaccination in the 
future—six in the COVID-19 vaccine alone group and 
three in the concomitant COVID-19 and influenza 
vaccine group. 11 (3%) of 356 participants in employment 
reported between 0·5 and 2 lost workdays after 
vaccination (appendix p 77). The Bang blinding indices 
for assessing the success of masking were 0·33 (95% CI 
0·26–0·40) for the group given concomitant COVID-19 
and influenza vaccines and 0·26 (0·19–0·33) in the 
group given the two vaccines separately (appendix p 77).
Discussion 
Our findings show that concomitant administration of 
six different combinations of COVID-19 and influenza 
vaccines raised no safety concerns, produced acceptable 
reactogenicity profiles, and preserved binding antibody 
responses. The systemic reactogenicity profiles were 
considered acceptable despite an increase in the rate of 
systemic events above 25% in two cohorts. In the 
ChAdOx1 plus MF59C adjuvanted, trivalent influenza 
vaccine cohort, the upper limit of the 95% CI only 
narrowly exceeded 25%, with most additional reactions—
predominantly fatigue, headache, and myalgia—
recorded as mild or moderate. The BNT162b2 plus 
recombinant quadrivalent influenza vaccine cohort was 
smaller than planned; therefore definitive conclusions 
are unable to be drawn. It is reassuring that most 
participants were supportive of concomitant vaccination.
The anti-spike immunoglobulin responses to both 
BNT162b2 and ChAdOx1 were preserved with all three 
types of influenza vaccine. The geometric mean ratios 
ranged between 0·80 and 1·13 for the six vaccine 
Figure 3: Anti-spike immunoglobulin geometric mean titre ratio between COVID-19 vaccine given with or 
without influenza vaccine
Placebo first indicates that COVID-19 vaccine alone was received at day 0. Influenza first indicates that 
concomitant COVID-19 and influenza vaccines were received at day 0. QIVc=cellular quadrivalent vaccine. 




Geometric mean ratio (95% CI)
Higher with placebo first Higher with influenza first
0·86 (0·72–1·03)BNT162b2 + QIVr (n=57)
0·92 (0·81–1·04)ChAdOx1 + QIVr (n=123)
0·97 (0·83–1·13)BNT162b2 + aTIV (n=78)
1·02 (0·91–1·14)ChAdOx1 + aTIV (n=141)
0·90 (0·80–1·01)BNT162b2 + QIVc (n=137)
0·92 (0·81–1·04)ChAdOx1 + QIVc (n=124)
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combinations evaluated. The geometric mean ratios in all 
six cohorts were above 0·67, which is the cutoff applied by 
WHO when approving new vaccines as non-inferior to 
existing products, using geometric mean ratio as an 
endpoint.12 This criterion acts as a useful reference point 
for contextualising our results in the absence of an agreed 
correlate of protection for COVID-19 vaccines. The 
humoral responses to all influenza vaccines were similar 
Figure 4: Haemagglutination inhibition influenza geometric mean ratios
Placebo first indicates that COVID-19 vaccine alone was received at day 0. Influenza first indicates that concomitant COVID-19 and influenza vaccines were received at day 0. QIVc=cellular quadrivalent 
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between groups within each cohort, except for the 
BNT162b2 plus recombinant quadrivalent influenza 
vaccine cohort, where geometric mean titres were 
significantly higher for three strains when given with the 
COVID-19 vaccine. It is possible that the RNA contained 
within BNT162b2, acting as adjuvant, augments responses. 
However, it is unclear why this would only influence the 
recombinant influenza vaccine and not the others.
To our knowledge, these are the first data to describe 
concomitant administration of any vaccine with either an 
adenovirus or mRNA COVID-19 vaccine, as previous trials 
have excluded those receiving other vaccines at or near the 
time of the COVID-19 vaccination.5,6 In a substudy of a 
phase 3 trial that assessed the safety and efficacy of a 
protein subunit COVID-19 vaccine with Matrix-M adjuvant 
(NVX-CoV2373), cellular quadrivalent influenza vaccine was 
co-administered to participants aged 18–64 years with the 
first dose of the two dose COVID-19 vaccine schedule.13,14 
Similar to our findings, Toback and colleagues14 found no 
significant differences in reactogenicity between those 
receiving concomitant vaccination compared with the 
COVID-19 vaccine alone. By contrast, a significant 
difference was seen in the geometric mean ELISA units 
between the group receiving concomitant vaccination 
versus COVID-19 vaccine alone, with a geometric mean 
ratio of 0·57 (95% CI 0·47–0·70), below the WHO 
0·67 geometric mean ratio cutoff, suggesting immune 
interference.14 Importantly, there was no difference in the 
efficacy of concomitant vaccination. The key difference 
between Toback and colleagues’ trial14 and ours is that the 
influenza vaccine was administered with the first dose, not 
the second dose, of COVID-19 vaccine.14 Pertinently, Toback 
and collegaues14 showed that higher geometric mean units 
were reached when the NVX-CoV2373 COVID-19 vaccine and 
influenza vaccine were co-administered to participants 
with serological evidence of previous COVID-19 infection. 
Natural infection with COVID-19 primes the immune 
system, resulting in significantly higher anti-spike IgG 
responses to the first dose of COVID-19 vaccine compared 
with those who are COVID-19 naive.15 This finding suggests 
that concomitant immunisation might effect priming but 
not subsequent responses, meaning that it might be 
optimal to co-administer an influenza vaccine with second 
or later doses of COVID-19 vaccine. However, given that the 
efficacy of the subunit COVID-19 vaccine was preserved 
despite a reduction in the humoral response, there would 
still be advantages of concomitant administration with the 
first dose of COVID-19 vaccine if this were necessary to 
prevent delays in the uptake of either vaccine. The effect of 
the immune interference with priming doses might have 
implications for less immunogenic COVID-19 vaccines, 
such as whole virion, inactivated vaccines.16
Concomitant administration of influenza vaccines with 
other vaccines has been studied for other vaccine types, 
including pneumococcal polysaccharide and conjugate 
vaccines.17,18 Relative reductions have been reported for 
some pneumococcal serotypes in some studies, but these 
have not proven to be clinically significant.7 These studies 
show that concomitant administration has no effect on 
humoral responses to influenza vaccine, consistent with 
the findings reported here.
The strengths of this trial are that we did not exclude 
individuals who were pregnant, had severe, uncontrolled 
medical problems, were immunocompromised, or aged 
65 years and over, so the trial population is reflective of 
the population who are most likely to receive both 
influenza and COVID-19 vaccines. The trial also included 
the two most widely used COVID-19 vaccines and the 
most frequently used influenza vaccine types, and so 
should be applicable in many settings.
The study has several limitations. The participant-
reported primary outcome is subject to potential bias. 
The influenza vaccine is likely to cause more local 
reactions than placebo, which could unmask the 
allocation. The Bang Blinding Index suggests that more 
participants guessed their allocation correctly than 
would be expected by chance. Given the novelty of the 
adenovirus and mRNA vaccines, it is not known whether 
these findings would apply to other COVID-19 vaccines 
in the same class. Similarly, whether these findings 
could apply to live, attenuated or high-dose influenza 
vaccines is a matter for discussion and further studies 
are required with these specific vaccine types. Two of the 
cohorts had lower recruitment than planned, which was 
related to the expiry dates of some influenza vaccines 
and the timing of the roll-out of specific COVID-19 
vaccines in the UK. The cellular quadrivalent influenza 
cohorts were added partway through the trial, which 
meant that the sites recruiting these cohorts enrolled 
participants into these two cohorts, whereas earlier sites 
recruited into four cohorts, which could affect the 
generalisability of results pertaining to the cellular 
quadrivalent influenza vaccine cohorts. The concomitant 
administration was done with a second dose of 
COVID-19 vaccine, and not third, booster doses, which 
are most likely to be administered with influenza 
vaccine. The absence of SARS-CoV2 neutralising 
antibody data in this report limits the evaluation of the 
humoral response. Finally, T-cell responses were not 
evaluated; it is clear that cellular immunity has a role in 
protection against natural SARS-CoV-2 infection and 
that vaccine-induced cellular responses might behave 
independently to neutralising antibodies; therefore 
further studies investigating T-cell responses to 
concomitant vaccination are warranted.19,20
In conclusion, there are no safety concerns raised in this 
trial over administering BNT162b2 and ChAdOx1 in adults 
alongside standard-dose inactivated influenza vaccines, 
including those with MF59C adjuvant. Concomitant 
vaccination with both COVID-19 and influenza vaccines 
over the next immunisation season should reduce the 
burden on health-care services for vaccine delivery, 
allowing for timely vaccine administration and protection 
from COVID-19 and influenza for those in need.
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